What's already known about this topic?
• Clinical studies, in addition to preclinical data, are required for regulatory approval of biosimilars.
• Biosimilar clinical trials are designed with smaller sample sizes than those required for approval of new biologic agents, and are not required for every indication of the originator.
What does this study add?
• The International Psoriasis Council provides suggestions for biosimilar clinical trial design and describes psoriasis as the best disease model for TNF blocker biosimilar studies.
Abstract
Biosimilars are drugs that are similar, but not identical, to originator biologics. Pre-clinical analytical studies are required to show similarity on a molecular and structural level, but efficacy and safety studies in humans are essential to ultimately determine biosimilarity. In this review written by members of the International Psoriasis Council, we discuss how biosimilars are evaluated in a clinical setting, with emphasis on extrapolation of indication, interchangeability, and optimal clinical trial design. (Table 1) . Although pre-clinical analytical studies represent the scientific foundation for biosimilars, efficacy and safety studies in humans remain the gold standard to confirm clinical equivalence and therefore biosimilarity. 2 Here, we discuss how biosimilarity is being defined on a clinical level.
Perhaps the biggest and most significant problem related to biologic prescribing and use for psoriasis patients has been the high cost of these products. 3 The signature promise of biosimilars is that they will decrease cost and increase access to biologic drugs for individuals who suffer from psoriasis, greatly improving the larger problem of under-treatment of this disease by dermatologists. 4 In order to reduce clinical development costs, clinical study requirements for regulatory agency approval of biosimilars are designed to be done with smaller sample sizes than those required for approval of new biologic agents, and need not be repeated for every indication of the originator. In other words, the amount and type of clinical data generated in clinical studies involving biosimilars will inherently be less than the clinical data obtained for originator biologics. Regarding this point, another purpose of this paper is to provide suggestions for optimal clinical study design as biosimilars proceed through development and regulatory hurdles.
Extrapolation in Biosimilar Clinical Studies
Page 5 of 34 British Journal of Dermatology   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 (Table 2) . Both the U.S. Food and Drug Administration (FDA) and the European Medical Agency (EMA) have published trial design guidelines for biosimilars. 5 6 Extrapolation is defined as the ability to utilize clinical study data for one disease to gain agency approval for another disease not explicitly studied in clinical trials. 7 8 For example, using the principle of extrapolation, the EMA recently approved a biosimilar infliximab product (marketed as Remsima and Inflectra) for psoriasis, psoriatic arthritis, and inflammatory bowel diseases when this biosimilar drug had undergone clinical testing in only two disease types: rheumatoid arthritis and ankylosing spondylitis (Table 3) . 9 Of note, showing similar clinical study results for biosimilar infliximab and Remicade in these latter two diseases does not necessarily mean that similar clinical results would be documented in other head-to-head studies with these same drugs when used in patients with psoriasis or psoriatic arthritis. As a result of this decision by the EMA, the dermatology community may find it difficult to interpret data collected from biosimilar trials done in dissimilar disease states.
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Health Canada, the drug regulating authority in Canada, has recently reached a somewhat different conclusion than the EMA regarding Remsima/Inflectra. These drugs were approved for use in inflammatory diseases of the skin (e.g., psoriasis) and joints (e.g., rheumatoid arthritis and psoriatic arthritis), but not for inflammatory bowel diseases. Health
Canada argued that extrapolation of data from rheumatoid arthritis/ankylosing spondylitis to psoriasis/psoriatic arthritis could be done, but not from the former diseases to Crohn's disease/ulcerative colitis. 11 They stated that differences in the results of an assay for antibodydependent cell-mediated cytotoxicity, a function of TNF blockers believed to be critical for 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Interchangeability in Biosimilar Clinical Studies
Interchangeability is the concept that a biosimilar drug and its parent biologic compound are so similar that a patient could be switched from one originator drug to another biosimilar drug and back during chronic therapeutic use, perhaps an indefinite number of times, without any untoward clinical side effects occurring due to this interchange of products. 17 18 The FDA defines interchangeability when a biosimilar "can be expected to produce the same clinical result as the reference product in any given patient; and for a product administered more than once, the safety and reduced efficacy risks of alternating or switching are not greater than with repeated use of the reference product." 5 The EMA defines interchangeability as the medical practice of changing one medicine for another that is expected to achieve the same clinical effect in a given clinical setting in any one patient, on the initiative, or with the agreement of the prescriber, 19 20 whereas automatic substitution, occurs when a prescribed medicine is substituted with another product by a pharmacist in the absence of physician notification. 2021 24 In France, automatic substitution (by community pharmacists) of a biologic with another belonging to the same biosimilar group is allowed to initiate or allow continuation of treatment, provided this possibility has not been ruled out by the prescriber. In the Netherlands automatic switching is allowed with patient's informed consent.
We suggest that biosimilars and originator biologics should not be randomly interchanged, since
it would be impossible to accurately assess loss of efficacy and adjudicate adverse effects in the setting where drug switching is occurring haphazardly. Rigorous clinical evidence is needed to assess the safety and efficacy of switching from an originator to a biosimilar product. In an extension study of PLANETRA, rheumatoid arthritis patients switched from infliximab to CT-P13 (Remsima) did not demonstrate loss of efficacy or increase in immunogenicity over two years compared to the group of patients that were started and maintained on CT-P13. 25,26 Similar findings were reported in the extension study (PLANETAS) in ankylosing spondylitis patients.
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However, it is important to note that these studies were not designed to test equivalency or noninferiority. Data from an Italian observational cohort study of inflammatory bowel disease patients demonstrated no differences in safety between patients switched from reference 
Optimal Clinical Study Design for Biosimilars
A biosimilar trial that aims to show both biosimilarity and interchangeability must address additional regulations and design specifications. 31 There are two conditions that are equally possible for a patient to encounter as outlined by Anderson and Hauck: 32 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 would allow for switching back and forth is three, and so the possible sequences of exposure are: RRR, BBB, RBR, BRB, RRB, RBB, BRR, and BBR ( Figure 1 ). This is the ideal, 8-sequence, 3-period (8 x 3) clinical trial design that would incorporate all potential situations a patient may encounter, but it may be less feasible than a RR, BB, RB, BR design.
Such a clinical trial design would also greatly aid in determining causality for an adverse event when drug switching is occurring. 33 Determining causality for an adverse event is potentially variable upon the half-life of the products, and any design chosen should allow for comparison to a cohort that does not switch. Since in the 8x3 design there are three cases in which a crossover occurs in the same direction, but at varying times, for both the reference product and the biosimilar group, how close an adverse event occurs to a switch could indicate whether accumulation of the initial product is the cause for the adverse event or not.
We suggest that a biosimilar trial should also be at least as long as the primary endpoint in the reference product's pivotal trials, and be based on the same safety measures collected during these original trials. For example, TNF blocker biosimilar trials should include safety outcomes such as deaths, malignancies, opportunistic infections, reactivation of tuberculosis and hepatitis B virus, major adverse cardiac events, and injection site reactions. The EMA stated they made the decision on biosimilar infliximab (CT-P13), and will continue to make approval and extrapolation decisions on future biosimilars, based on the totality of evidence presented by biosimilar companies. In other words, the biosimilar product should not show any meaningful differences from the reference medicine in terms of its quality, safety, and efficacy. Biosimilar applications must include extensive pre-clinical analytical data on the structure and function of the drugs, pharmacokinetics/pharmacodynamics information, and clinical studies on efficacy and safety (benefits/risks ratio, risk of immune reactions, immunogenicity) equivalence. 34 Additionally, in terms of efficacy, it is necessary to demonstrate clinical equivalence on efficacy and safety of the biosimilar and the reference biologic in adequately powered, randomized, parallel group, preferably double-blinded, comparative clinical trials. 35 The European Commission recently approved a second TNF-α infliximab biosimilar (Flixabi) for all indications in the 28 European Union member states and also the European Economic Area member countries of Norway, Liechtenstein, and Iceland. Although the EMA has demonstrated their support for indication extrapolation in the case of TNF blockers, the concern is that similar efficacy or safety between biosimilar and originator biologic may not be demonstrated in diseases that are not directly studied.
EMA and FDA Guidelines on Biosimilar Clinical Studies
The Patient Protection and Affordable Care Act provided U.S. guidelines for biosimilar approvals. 36 Clinical data needed for FDA approval of biosimilar drugs require less extensive studies than for the originator drugs. 5 Either a phase I or phase III trial in patients with a disease for which the originator product is licensed is needed to establish biosimilarity. 37 A pharmaceutical company producing a biosimilar stated at an investigator meeting that they intended to have one phase 1 trial for pharmacokinetics and a single pivotal phase 3 trial faced with drugs approved for psoriatic arthritis that were only studied in psoriasis. 45 The primary endpoints of equivalence trials must not be the same that were used in clinical trials of the originator biologics. The FDA requires biosimilars to show similar efficacy to originator biologics, namely that the proposed product has neither decreased nor increased activity compared to the reference product.
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Summary
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